study demonstrated the biological and clinical significance of TRIM28 expression in non-small cell lung cancer; overexpression of TRIM28 was likely to be an essential contributor to a growth promotion of NSCLCs

results suggest a model in which Trim28 is a tumor suppressor early in the transformation process in lung cancer, but in later stages it functions as an oncogene

Cell proliferation and apoptosis were almost completely abolished in the PAa cells cotreated with TRIM28 siRNA and etoposide following knockdown of E2F1. The results of our study demonstrated that the combination of TRIM28 siRNA and etoposide may be effective against nonsmall cell lung cancer (NSCLC)and has the potential of being a new therapeutic tool for future treatment.

Data suggest that tripartite motif-containing 28 protein (KAP1) may represent a potential diagnosis biomarker and new treatment target for lung cancer.

TRIM28 is a distinct prognostic biomarker that worsens the tumor immune microenvironment in lung adenocarcinoma.